Management of Diabetes in Patients with Chronic Kidney Disease

References

• . Orchard TJ, Dorman JS, Maser RE, . Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39(9):1116–1124
   PubMedGoogle Scholar
• . Newman DJ, Mattock MB, Dawnay AB, . Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess. 2005;9:iii–iv
   PubMedGoogle Scholar
• . US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004
   Google Scholar
• . Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–787
   PubMed Web of Science ®Google Scholar
• . Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int. 1991;40(4):792–807
   PubMedGoogle Scholar
• . Vora JP, Dolben J, Dean JD, . Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int. 1992;41(4):829–835
   PubMedGoogle Scholar
• . Nelson DG, Bennett, PH, Beck GJ, . Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med. 1996;335(22):1636–1642
   PubMedGoogle Scholar
• . National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39( suppl 1):S1–S266
   PubMed Web of Science ®Google Scholar
• . Warram JH, Gearing G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7(6):930–937
   PubMedGoogle Scholar
• . KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12–S154
   PubMed Web of Science ®Google Scholar
• . Fröhlich J, Schollmeyer P, Gerok W. Carbohydrate metabolism in renal failure. Am J Clin Nutr. 1978;31(9):1541–1546
   PubMedGoogle Scholar
• . Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006;17(4 suppl 2):S145–S147
   PubMedGoogle Scholar
• . Johnson RJ, Alpers CE, Yoshimura A, . Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19(5):464–474
   PubMedGoogle Scholar
• . Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865–879
   PubMedGoogle Scholar
• . Rigalleau V, Blanchetier V, Combe C, . A low-protein diet improves insulin sensitivity of endogenous glucose production in predialytic uremic patients. Am J Clin Nutr. 1997;65(5):1512–1516
   PubMedGoogle Scholar
• . Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol. 2005;16(2):459–466
   PubMedGoogle Scholar
• . Ibrahim H, Mondress M, Tello A, Fan Y, Koopmeiners J, Thomas W. An alternative formula to the Cockcroft-Gault and the modification of diet in renal diseases formulas in predicting GFR in individuals with type 1 diabetes. J Am Soc Nephrol. 2005;16(4):1051–1060
   PubMedGoogle Scholar
• . Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52(4):1036–1040
   PubMedGoogle Scholar
• . Lane PH, Steffes MW, Mauer SM. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes. 1992;41(5):581–586
   PubMedGoogle Scholar
• . Jacob J, Tsao PS. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits. Am J Nephrol. 2007;28(2):224–237
   PubMedGoogle Scholar
• . Paoletti E, Bellino D, Amidone M, Rolla D, Cannella G. Relationship between arterial hypertension and renal damage in chronic kidney disease: insights from ABPM. J Nephrol. 2006;19(6):778–782
   PubMedGoogle Scholar
• . UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Fonesca V, Katholi RE, . Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292(18):2227–2236
   PubMed Web of Science ®Google Scholar
• . Fellstrom BC, Jardine AG, Schmieder RE, . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Wanner C, Krane V, März W, . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
   PubMed Web of Science ®Google Scholar
• . Gansevoort RT, Vaziri RD, de Jong PE. Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Am J Kidney Dis. 1996;28(2):274–277
   PubMedGoogle Scholar
• . Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(1):1011–1023
   PubMedGoogle Scholar
• . Tuttle KR Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement insulin-dependent diabetes mellitus. N Engl J Med. 1991;324(23):1626–1632
   PubMedGoogle Scholar
• . Hirschberg R, Brunori G, Kopple JD, Guler HP. Effects of insulinlike growth factor I on renal function in normal men. Kidney Int. 1993;43(2):387–397
   PubMedGoogle Scholar
• . Hirschberg R, Kopple JD. The growth hormone-insulin-like growth factor I axis and renal glomerular filtration. J Am Soc Nephrol. 1992;2(9):1417–1422
   PubMedGoogle Scholar
• . Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int. 1996;49(6):1795–1804
   PubMedGoogle Scholar
• . Passariello N, Sepe J, Marrazzo G, . Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care. 1993;16(5):789–795
   PubMed Web of Science ®Google Scholar
• . Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57(5):1803–1817
   PubMedGoogle Scholar
• . Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335–342
   PubMed Web of Science ®Google Scholar
• . Mogensen CE, Neldam S, Tikkanen I, . Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440–1444
   PubMed Web of Science ®Google Scholar
• . Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. Horm Metab Res. 2005;37( suppl 1):4–8
   PubMedGoogle Scholar
• . Schjoedt KJ, Rossing K, Juhl TR, . Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–2836
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008:358(15): 1547–1559
   PubMed Web of Science ®Google Scholar
• . Triplitt C. Drug interactions of medications commonly used in diabetes. Diabetes Spectrum. 2006;19:202–211
   Google Scholar
• . Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341(8856):1306–1309
   PubMed Web of Science ®Google Scholar
• . The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Ohkubo Y, Kishikawa H, Araki E, . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117
   PubMed Web of Science ®Google Scholar
• . Yu CC, Wu MS, Wu CH, . Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997;17(3):262–268
   PubMedGoogle Scholar
• . Morioka T, Emoto M, Tabata T, . Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24(5):909–913
   PubMedGoogle Scholar
• . Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23( suppl 2):B21–B29
   PubMed Web of Science ®Google Scholar
• . Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304–309
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963–1972
   PubMed Web of Science ®Google Scholar
• . Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110
   PubMed Web of Science ®Google Scholar
• . Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol. 2005;16( suppl 1):S7–S10
   PubMedGoogle Scholar
• . Inoue T, Shibahara N, Miyagawa K, . Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60(2):90–95
   PubMed Web of Science ®Google Scholar
• . Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003;59(3):191–194
   PubMed Web of Science ®Google Scholar
• . Schumacher S, Abbasi I, Weise D, . Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57(2):147–152
   PubMed Web of Science ®Google Scholar
• . Snyder RW, Berns JS. Use of insulin and oral hypoglcemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17(5):365–370
   PubMed Web of Science ®Google Scholar
• . Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17:79–12
   Google Scholar
• . Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50(10):1193–1196
   PubMedGoogle Scholar
• . Guan Y, Hao C, Cha DR, . Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11(8):861–866
   PubMed Web of Science ®Google Scholar
• . Nesto RW, Bell D, Bonow RO, . Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–2948
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed April 30, 2009
   Google Scholar
• . Lincoff MA, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298(10):1180–1188
   PubMed Web of Science ®Google Scholar
• . Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174–183
   PubMed Web of Science ®Google Scholar
• . Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Nephrol Dial Transplant. 2006;21(2):553–554
   PubMedGoogle Scholar
• . Lepore M, Pampanelli S, Fanelli C, . Pharmacokinetics and pharmacodynamics of subcutaneous injection of long acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000:49(12);2142–2148
   PubMedGoogle Scholar
• . Bott S, Tusek C, Jacobsen LV, . Insulin detemir under steady state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabetic Medicine. 2006;23:522–528
   PubMed Web of Science ®Google Scholar
• . Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol. 2002;13( suppl 1):S92–96
   PubMedGoogle Scholar
• . Morioka T, Emoto M, Tabata T, . Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24(5):909–913
   PubMedGoogle Scholar
• . Sangill M, Pedersen EB. The effect of glucose added to the dialysis fluid on blood pressure, blood glucose and quality of life in hemodialysis patients: a placebo-controlled crossover study. Am J Kidney Dis. 2006, 47(4): 636–643
   PubMedGoogle Scholar
• . Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis. 2003;41(3):523–531
   PubMedGoogle Scholar
• . Sato T, Inagaki A, Uchida K, . Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosoprine A-based therapy. Transplantation. 2003;76(9):1320–1326
   PubMedGoogle Scholar
• . Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis. 1999;34(1):1–13
   PubMedGoogle Scholar
• . Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ. Early steroid withdrawal therapy in renal transplantation recipients: a steroid free sirolimus and CellCept based calcineurin inhibitor-minimization protocol. Clin Transplant. 2007;21(1):101–109
   PubMedGoogle Scholar
• . Kim YS, Kim MS, Kim SI, Lim SK, Lee HY, Han DS, Park K. Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: a prospective trial in renal transplants. Transpl Int. 1997;10(3):197–201
   PubMedGoogle Scholar
• . Van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2004;19( suppl 6):vi8–vi12
   PubMedGoogle Scholar
• . Naschitz JE, Barak C, Yeshurun D. Reversible diminished insulin requirement during acute renal failure. Postgrad Med J. 1983;59(690):269–271
   PubMedGoogle Scholar
• . O'Hare A, Johansen K. Lower extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12(12):2838–2847
   PubMedGoogle Scholar
• . Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar